Source: Eur Respir J, 49 (5) 1601847; 10.1183/13993003.01847-2016
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Muhammad-Hariri Mustafa, Shaunak Khandekar, Michael M. Tunney, J. Stuart Elborn, Barbara C. Kahl, Olivier Denis, Patrick Plésiat, Hamidou Traore, Paul M. Tulkens, Francis Vanderbist, Françoise Van Bambeke. Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients. Eur Respir J, 49 (5) 1601847; 10.1183/13993003.01847-2016

Member's Comments

No comment yet.

Related content which might interest you: Variability of ß-lactamase resistance Pseudomonas aeruginosa genes infecting patients with cystic fibrosis Source: Virtual Congress 2021 – Back to infection basics Year: 2021 Eradication of Pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2006; 27: 653 Year: 2006 Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa Source: Eur Respir J 2003; 22: 503-506 Year: 2003 Factors associated with infection by Pseudomonas aeruginosa in adult cystic fibrosis Source: Eur Respir J 2005; 26: 651-656 Year: 2005 Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis}, Source: Eur Respir J 2012; 40: 1014-1023 Year: 2012 Characterization of the resistance mechanisms to carbapenems and virulence genes in Pseudomonas aeruginosa strains from children with cystic fibrosis. Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021 Eradication of Pseudomonas aeruginosa in cystic fibrosis Source: Eur Respir J 2006; 27: 438-439 Year: 2006 Epidemiological-molecular study of colonization by pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 379s Year: 2002 Daily versus weekly azithromycin in cystic fibrosis patients Source: Eur Respir J 2007; 30: 487-495 Year: 2007 Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre Source: Eur Respir J 2005; 25: 474-481 Year: 2005 Antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis – clinical application Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research Year: 2018 Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005 Omics-based tracking of Pseudomonas aeruginosa persistence in “eradicated” cystic fibrosis patients Source: Eur Respir J, 57 (4) 2000512; 10.1183/13993003.00512-2020 Year: 2021 Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2007; 30: 286-292 Year: 2007 Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre Source: Eur Respir J 2006; 27: 937-943 Year: 2006 Azithromycin in chronic respiratory infections with pseudomonas aeruginosa in patients without cystic fibrosis Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host Year: 2008 Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients Source: Eur Respir J 2008; 31: 822-829 Year: 2008 Chronic use of azithromycin in CF is associated with a substantial increase in macrolide resistance of S. aureus and haemophilus Source: Annual Congress 2006 - Cystic fibrosis lung disease: molecules images and drugs Year: 2006 Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014